Tirzepatide — Research Reference

Tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for weight management) is a synthetic 39-amino-acid peptide that acts as a dual agonist at the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual mechanism differentiates it from semaglutide (GLP-1 only), and clinical trial data suggests greater weight reduction efficacy at comparable doses.

Quick Reference

Parameter	Reported Value
Full name	Tirzepatide
Amino acids	39
Molecular weight	~4,814 Da
Half-life	~5 days (reported; supports once-weekly dosing)
Common reported doses	2.5 mg/week (starting) to 15 mg/week (maximum studied)
Administration route	Subcutaneous injection
Storage	Refrigerator; in-use pen stable at room temperature up to 21 days
Regulatory status	Approved pharmaceutical (Mounjaro, Zepbound) in multiple jurisdictions

Overview

Tirzepatide was developed by Eli Lilly and Company and is approved as a pharmaceutical — as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Like semaglutide, it is both an approved clinical medicine and a widely circulated research compound.

The addition of GIP receptor agonism to GLP-1 receptor agonism distinguishes tirzepatide from first-generation GLP-1 monotherapy. The proposed mechanisms of GIP co-activation include:

Augmented insulin secretion via a complementary pancreatic pathway
Improved tolerability compared to pure GLP-1 agonism (GIP receptor activation may modulate GLP-1-mediated nausea)
Potential enhancement of fat cell metabolism via peripheral GIP receptor activity

The SURMOUNT-1 clinical trial reported a mean weight reduction of approximately 22.5% over 72 weeks at the 15 mg weekly dose — the largest weight reduction reported in a phase 3 metabolic peptide trial to date at the time of publication.

Reported Protocols

Standard Clinical Escalation Protocol

Tirzepatide shares the GI tolerability challenges of GLP-1 class compounds. Gradual dose escalation is standard in both clinical use and anecdotal research contexts.

The escalation schedule from SURMOUNT and SURPASS trials:

Weeks 1–4: 2.5 mg once weekly (initiation; not the therapeutic dose)
Weeks 5–8: 5.0 mg once weekly
Weeks 9–12: 7.5 mg once weekly
Weeks 13–16: 10 mg once weekly
Weeks 17–20: 12.5 mg once weekly
Week 21 onward: 15 mg once weekly (maximum studied dose)

Anecdotal research accounts frequently describe pausing at an intermediate dose (5–10 mg) when side effects are prominent, and resuming escalation when tolerability improves. Some researchers remain at a maintenance dose below 15 mg long-term based on individual response.

Semaglutide Transition

Anecdotal accounts describe transition from semaglutide to tirzepatide in research contexts. No standard transition protocol exists in the published literature, though researchers have described switching directly at an approximately equipotent dose.

Reported Effects

The following effects have been reported in clinical research and anecdotal accounts. This list reflects the research landscape, not confirmed outcomes for all individuals.

Weight Reduction

The SURMOUNT-1 trial (n = 2,539) reported a mean weight reduction of approximately 22.5% at 15 mg weekly over 72 weeks. Participants achieving the maximum dose showed greater than 20% weight reduction on average, with a significant proportion exceeding 25%. The SURMOUNT-5 trial (2024) compared tirzepatide directly to semaglutide and reported approximately 20% greater weight reduction with tirzepatide.

Appetite Suppression

Anecdotal reports frequently describe pronounced appetite reduction and reduced interest in food, including a reported reduction in food cravings. The dual mechanism is proposed to produce more complete appetite suppression than GLP-1 agonism alone.

Glycaemic Control

In type 2 diabetes research (SURPASS programme), tirzepatide demonstrated HbA1c reductions of approximately 2.0–2.3% — among the greatest reported for any approved compound in its class.

Metabolic Improvements

Reductions in triglycerides, improvement in HDL cholesterol, and improvements in blood pressure have been reported in clinical trial data. Research into tirzepatide’s potential role in non-alcoholic fatty liver disease (MASH) is ongoing.

Comparison to Semaglutide

Direct comparison data from SURPASS-2 and SURMOUNT-5 indicates greater HbA1c reduction and greater weight loss with tirzepatide compared to semaglutide at commonly used clinical doses. The GI side effect profile is reported as broadly similar, though tirzepatide may be better tolerated by some individuals due to the modulating effect of GIP receptor co-activation.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following.

Side Effect	Frequency Reported
Nausea	Very common, particularly during escalation
Diarrhoea	Common
Vomiting	Common
Constipation	Common
Decreased appetite	Very common
Injection site reactions	Occasionally reported
Abdominal discomfort	Common
Fatigue	Occasionally reported

Serious reported concerns:

Pancreatitis: Reported with GLP-1 class compounds; persistent abdominal pain warrants medical evaluation.
Gallbladder disease: Cholelithiasis and cholecystitis reported; likely related to rapid weight loss.
Thyroid C-cell effects: As with other GLP-1 agonists, rodent studies showed thyroid C-cell changes. Human relevance is not established. Individuals with medullary thyroid carcinoma history or MEN2 are excluded from clinical protocols.
Muscle mass loss: Lean mass loss alongside fat loss has been reported. Resistance training and adequate protein intake are frequently described in anecdotal research accounts as mitigation strategies.
Hypoglycaemia: Rare in individuals without diabetes; more relevant in research contexts involving insulin-sensitising co-treatments.

Storage & Handling

Licensed Pharmaceutical Product (Mounjaro / Zepbound)

Unused pens: Refrigerate (2–8°C) until the expiry date
In-use pens: May be stored at room temperature (below 30°C) for up to 21 days
Do not freeze; protect from direct heat and sunlight
Replace pen cap and dispose of needle after each use

Research Compound (Lyophilized / Reconstituted)

Lyophilized: Refrigerator preferred; room temperature stable short-term; protect from light and moisture; avoid freeze-thaw cycles
Reconstituted: Refrigerate; use within 4–6 weeks; do not freeze

See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

Is tirzepatide the same as Mounjaro? Mounjaro and Zepbound are brand names for tirzepatide. Mounjaro is approved for type 2 diabetes management. Zepbound is approved for chronic weight management. The active compound in both is tirzepatide; the distinction is the approved indication and the prescribing population each brand targets. The dose range and formulation are the same across both brands.

How does tirzepatide differ from semaglutide? Tirzepatide is a GLP-1/GIP dual agonist; semaglutide is a GLP-1 monotherapy. Clinical trial data from direct head-to-head studies has reported greater weight reduction and HbA1c reduction with tirzepatide at comparable doses. The GI side effect profiles are broadly similar, though GIP co-activation may improve tolerability for some individuals. See the Semaglutide page for comparison.

What is the difference between Mounjaro and Zepbound? Both contain tirzepatide. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. The active compound and dose range are identical; the indication and approved prescribing population differ.

What is the maximum dose? The maximum dose studied in clinical trials is 15 mg weekly. Clinical practice and anecdotal research accounts frequently describe long-term maintenance at 10–15 mg, with some individuals achieving satisfactory outcomes at lower doses.

Does tirzepatide work better than retatrutide? Direct head-to-head data between tirzepatide and retatrutide is not yet available from completed Phase 3 trials. Phase 2 retatrutide data reported greater mean weight loss (~24%) than tirzepatide Phase 3 data (~22%), but cross-trial comparisons are unreliable due to population and design differences. See the Retatrutide page for further detail.

Goals: Fat Loss · Metabolic Health · Appetite & Weight Management

Class: GLP-1 / GIP / Glucagon Agonists

Comparisons: Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide

References & Further Reading

Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. PubMed →
Frias JP, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. PubMed →
Dahl D, et al. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. JAMA, 327(17), 1719–1728. PubMed →